Wolfe Research analyst Alex Zukin maintains Informatica (NYSE:INFA) with a Outperform and lowers the price target from $25 to $20.
Astria Therapeutics Presents New Phase 1a Data Confirming Potential For STAR-0125 To Prevent Hereditary Angioedema Attacks With Dosing 2 Or 4 Times Per Year At The 2023 American College Of Allergy, Asthma, And Immunology Annual Scientific Meeting
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster presentation at the
